Lacey Campbell, NP
Nurse Practitioner · Oklahoma City, OKNPI 1093322240
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,772 of the $12,792 with a category attached, or 60.8%. 30 manufacturers reported payments, led by Corcept Therapeutics at 39.8% of the total. 2025 is the largest year on record at $6,939, 8.3 times the $837 reported in 2021. Among nurse practitioner clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 376 payments — averaging $34.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$5K
- Medtronic$1K
- Dexcom, Inc.$1K
- Lilly USA, LLC$701
- Xeris Pharmaceuticals, Inc.$541
- Tandem Diabetes Care, Inc.$495
- plus $4K from 24 others
What the payments were for
- Speaking & faculty fees$3,42027%
- Travel & lodging$1,60013%
- Food & beverage$7,77261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 39 | $5,089 |
| Medtronic | 14 | $1,373 |
| Dexcom, Inc. | 44 | $1,041 |
| Lilly USA, LLC | 42 | $701 |
| Xeris Pharmaceuticals, Inc. | 29 | $541 |
| Tandem Diabetes Care, Inc. | 21 | $495 |
| Novo Nordisk | 28 | $441 |
| Sanofi-aventis U.S. LLC | 22 | $434 |
| Boehringer Ingelheim | 16 | $304 |
| Bayer | 17 | $257 |
| Recordati_rare_diseases_inc. | 11 | $247 |
| Insulet Corporation | 10 | $209 |
| AstraZeneca(2 entities) | 4 | $190 |
| IBSA Pharma Inc. | 8 | $185 |
| Amgen | 9 | $171 |
| Sequel Med Tech, LLC | 10 | $166 |
| AbbVie | 10 | $144 |
| Antares Pharma, Inc. | 7 | $120 |
| Ascendis Pharma Endocrinology Inc | 4 | $102 |
| Chiesi USA, Inc. | 4 | $92 |
| BETA Bionics, Inc. | 7 | $82 |
| Novartis | 4 | $74 |
| Mannkind Corporation | 3 | $59 |
| Amneal Pharmaceuticals LLC | 3 | $56 |
| Cequr Corporation | 2 | $49 |
| Nevro Corp. | 2 | $48 |
| Astellas Pharma US Inc | 3 | $47 |
| Kyowa Kirin, Inc. | 1 | $29 |
| Neurocrine Biosciences, Inc. | 1 | $25 |
| Ascensia Diabetes Care US Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$4,230
- INPEN SMART INSULIN DELIVERY SYSTEM$499
- InPen$432
- DEXCOM G6 TRANSMITTER$233
- BREZTRI$124
How this compares
$12,792 in reported general payments places this provider in the 95th percentile of 824 nurse practitioner providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 17 | $805,944 |
| MounjaroTirzepatide | 376 | $612,464 |
| OzempicSemaglutide | 238 | $317,413 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 136 | $145,111 |
| Tresiba Flextouch U-200Insulin Degludec | 110 | $119,371 |
| JardianceEmpagliflozin | 89 | $101,752 |
| TrulicityDulaglutide | 50 | $78,096 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 32 | $38,341 |
| SynjardyEmpagliflozin/Metformin Hcl | 24 | $33,741 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 16 | $28,324 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $24,733 |
| FarxigaDapagliflozin Propanediol | 20 | $19,460 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 12 | $17,320 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 11 | $15,766 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $12,362 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $5,089 | $805,94417 claims |
| Lilly USA, LLCMounjaro, Trulicity | $701 | $690,560426 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Trijardy Xr, Synjardy | $304 | $318,945281 claims |
| Novo NordiskOzempic | $441 | $317,413238 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $434 | $28,32416 claims |
| AstraZenecaFarxiga | $190 | $19,46020 claims |
| AbbVieSynthroid | $144 | $3,59835 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $56 | $1,418125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 824 nurse practitioner providers in Oklahoma.
Other nurse practitioner in Oklahoma City
- Sara GoreOklahoma City$52K
- Russell RoomsOklahoma City$24K
- Grant YoungOklahoma City$15K
- Janelle WagnerOklahoma City$13K
- Stefanie RollinsOklahoma City$13K
- Stacey Waggoner FisherOklahoma City$9K
- Karie StewartOklahoma City$9K
- Lori CraigOklahoma City$8K
- Jennifer LewisOklahoma City$6K
- Theresa BachOklahoma City$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.